Guggenheim Maintains Buy on CryoPort, Raises Price Target to $16
Guggenheim analyst Subbu Nambi maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $12 to $16.
Stocks · News reference
Cryoport’s IntegriCell Cryopreservation Services Selected By Verismo Therapeutics To Support SynKIR-110 And SynKIR-310 Multi-Chain KIR-CAR Programs
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CryoPort shares are trading higher after the company reported better-than-expected Q2 sales results. Also, Needham maintained a Buy rating on the stock and raised its price target from $15 to $19.
Needham Maintains Buy on CryoPort, Raises Price Target to $19
Needham analyst David Saxon maintains CryoPort (NASDAQ:CYRX) with a Buy and raises the price target from $15 to $19.
Conference Call: CryoPort Affirms FY2026 Sales Guidance of $192.000M-$196.000M vs $194.390M Est
CryoPort (NASDAQ:CYRX) affirms FY2026 sales outlook from $192.000 million-$196.000 million to $192.000 million-$196.000 million vs $194.390 million estimate.